A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of Administering Repeated Doses of ALECSAT to Prostate Cancer Patients.
Phase of Trial: Phase I
Latest Information Update: 13 Jun 2014
At a glance
- Drugs Cancer vaccine-ALECSAT (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors CytoVac
- 07 Jun 2017 Biomarkers information updated
- 01 Jan 2013 Clinical trial report submitted to the Central Research Ethics Committee, according to a CytoVac media release.
- 01 Oct 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.